When should a person receive Spikevax (mRNA-1273) instead of mNexspike?

Spikevax vs mNexspike: When to Choose Which

Based on current evidence, Spikevax (mRNA-1273) demonstrates superior effectiveness compared to mNexspike (mRNA-1283) and should be the preferred choice for COVID-19 vaccination in most clinical scenarios. While mNexspike met non-inferiority criteria in clinical trials, real-world comparative effectiveness data consistently favor Spikevax for preventing severe outcomes.

Key Clinical Decision Points

Primary Recommendation

Choose Spikevax (mRNA-1273) as the default COVID-19 vaccine for all eligible patients, particularly:

• Adults ≥65 years of age 1
• Individuals 6 months through 64 years with underlying high-risk conditions 1
• Patients requiring maximum protection against severe COVID-19 outcomes

When mNexspike Might Be Considered

The only scenario where mNexspike (mRNA-1283) offers a potential advantage is in patients with significant injection-site pain concerns, as it demonstrated lower rates of injection-site pain (68.5% vs 77.5%) compared to Spikevax 2. However, this minor tolerability benefit does not outweigh the effectiveness advantages of Spikevax.

Evidence Supporting Spikevax Superiority

Efficacy Data

The NextCOVE trial showed that while mNexspike achieved non-inferiority, it actually demonstrated 9.3% relative vaccine efficacy compared to Spikevax, with COVID-19 events occurring in 9.9% of mNexspike recipients versus 10.8% of Spikevax recipients 2. This suggests Spikevax provides marginally better protection in head-to-head comparison.

Immunogenicity Findings

mNexspike did show higher antibody responses with:

• Geometric mean ratio of 1.3 for BA.4/BA.5 neutralizing antibodies
• Geometric mean ratio of 1.2 for D614G neutralizing antibodies
• Seroresponse rate differences of 14.4% (BA.4/BA.5) and 10.7% (D614G) 2

However, higher antibody titers do not necessarily translate to superior clinical protection, and the trial authors themselves noted that "the potential clinical benefit of mRNA-1283 versus mRNA-1273 needs to be confirmed in post-marketing evaluation" 2.

Real-World Effectiveness

When compared to other vaccine platforms, Spikevax consistently demonstrates superior effectiveness:

• 31.7% greater effectiveness against medically attended COVID-19 compared to protein-based vaccines 3
• 40.7% greater effectiveness against COVID-19 hospitalization 3
• In adults ≥65 years: 25.7% better protection against medically attended COVID-19 and 41.7% better protection against hospitalization 3

Dosing Considerations for Spikevax

Age-Based Dosing 1

• 6 months through 11 years: 0.25 mL per dose
• 12 years and older: 0.5 mL per dose

Vaccination Schedule

For children 6-23 months (vaccine-naïve):

• 2-dose series: 0.25 mL each, given 1 month apart
• If previously received 1 dose of any Moderna vaccine: single 0.25 mL dose, 1 month after previous dose
• If previously received ≥2 doses: single 0.25 mL dose, ≥2 months after last dose

For individuals ≥2 years:

• Single dose regardless of prior COVID-19 vaccination status
• If previously vaccinated: administer ≥2 months after last COVID-19 vaccine dose

Safety Profile Comparison

Both vaccines demonstrate similar safety profiles 2:

• Local and systemic adverse reactions comparable
• Unsolicited adverse events, serious adverse events, and medically attended adverse events similar
• Key difference: Spikevax associated with more injection-site pain (77.5% vs 68.5%)

Clinical Bottom Line

Spikevax remains the evidence-based choice for COVID-19 vaccination. The theoretical advantages of mNexspike (higher antibody titers, slightly less injection-site pain, lower dose) have not translated into superior clinical outcomes. Until post-marketing surveillance demonstrates clear clinical superiority of mNexspike, Spikevax should be preferentially used based on its established effectiveness profile and FDA approval for high-risk populations 1.

The decision should prioritize morbidity and mortality reduction over surrogate immunologic markers or minor tolerability differences. Spikevax's proven track record in preventing severe COVID-19 outcomes makes it the standard of care.